Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
Open Access
- 1 April 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (8) , 3749-3759
Abstract
Aim: This phase I, multicentre, open‐label, nonrandomised, parallel‐group, two‐part study aimed to evaluate the effect of mild to moderate hepatic impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of risdiplam.Methods: Adult subjects (aged 18‐70 years) with mild (Child‐Pugh Class A; Part 1) or moderate (Child‐Pugh Class B; Part 2) hepatic impairment were matched with subjects with normal hepatic function on sex, age, body mass index and smoking status. Each subject received a single oral dose of 5 mg of risdiplam. Plasma concentrations of risdiplam and its metabolite M1 were measured and PK parameters were compared. Adverse events, laboratory abnormalities, vital signs and electrocardiogram measurements were assessed.Results: After a single dose (5 mg) of risdiplam, the risdiplam PK parameters area under the plasma concentration‐time curve from time zero to infinity and maximum observed plasma concentration were approximately 20% and 5% lower, respectively, in subjects with mild hepatic impairment and approximately 8% and 20% higher, respectively, in subjects with moderate hepatic impairment compared with subjects with normal hepatic function. These differences were not statistically significant; all 90% confidence intervals for geometric least squares‐means ratios spanned unity. No new risdiplam‐related safety findings were observed in subjects with mild or moderate hepatic impairment.Conclusion: Mild or moderate hepatic impairment did not have a clinically relevant impact on the PK of risdiplam. Therefore, no dose adjustment is required in patients with mild or moderate hepatic impairment when receiving risdiplam.Keywords
Funding Information
- Roche
This publication has 13 references indexed in Scilit:
- Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organsPharmacology Research & Perspectives, 2018
- A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifierBritish Journal of Clinical Pharmacology, 2018
- Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)2018
- Pharmacokinetic drug interactions in liver disease: An updateWorld Journal of Gastroenterology, 2016
- A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophyProceedings of the National Academy of Sciences, 1999
- Quantitative Analysis of Survival Motor Neuron Copies: Identification of Subtle SMN1 Mutations in Patients with Spinal Muscular Atrophy, Genotype-Phenotype Correlation, and Implications for Genetic CounselingThe American Journal of Human Genetics, 1999
- When Is a Deletion Not a Deletion? When It Is ConvertedThe American Journal of Human Genetics, 1997
- Identification of Proximal Spinal Muscular Atrophy Carriers and Patients by Analysis of SMNT and SMNC Gene Copy NumberThe American Journal of Human Genetics, 1997
- A novel nuclear structure containing the survival of motor neurons protein.The EMBO Journal, 1996
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995